WGS
GeneDx Holdings Corp.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$85.99
−1.60%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
131.2x
EV/EBITDA
−34.0x
Market Cap
$2.56B
MomentumView details →
1D Return
−1.60%
YTD Return
−34.74%
RSI (14)
58.4
ValuationView details →
P/E (Fwd)
131.2x
EV/EBITDA
−34.0x
Market Cap
$2.56B
RSI (14)
58.4
MomentumView details →
1D Return
−1.60%
YTD Return
−34.74%
SummaryUpdated Jun 1, 2026
GeneDx Holdings Corp. (NASDAQ:WGS) is a patient-centered health intelligence company founded by Eric Schadt in October 2015 and headquartered in Stamford, Connecticut. The company went public in November 2020 and has established itself as a leader in genetic testing, particularly in pediatric and rare disease genomics. GeneDx operates the Centrellis health intelligence platform, which applies artificial intelligence and machine learning to clinical and genomic data to build comprehensive models of human health and provide personalized medical insights.
Similar companies
Latest newsMore news →
GeneDx Holdings Corp (WGS) shares rose 5.1% to $81.83 on August 11, 2026, in a volatile market.24d agoGeneDx launched a new online offering to improve accessibility of exome testing for children with global developmental delay, intellectual disability, and epilepsy.24d agoGeneDx Holdings Corp. announced a private placement of 81,967 Class A shares at US$61.00 each, with participation from a Blackstone affiliate.28d ago